The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Clinical Implications of Basic Research
PreviousPrevious
Volume 353:949-950 September 1, 2005 Number 9
NextNext

Treating Cancer by Targeting a Weakness
Lawrence C. Brody, Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
When it comes to antitumor drugs, both the physicians who prescribe them and the patients who receive them would agree that better chemotherapeutic agents are needed. Drugs in common use were designed to take advantage of general characteristics of tumor cells such as hormone responsiveness or high rates of cell division. Unfortunately, these properties are also found in some healthy cells. This general lack of specificity has led to the use of drug doses that straddle a knife edge between efficacy and toxicity. Two recent studies, one by Bryant et al.1 and the other by Farmer et al.,2 suggest that . . . [Full Text of this Article]


Source Information

From the Genome Technology Branch of the National Human Genome Research Institute, National Institutes of Health, Bethesda, Md.


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.